Non-Hodgkin Lymphoma | Tumor

Enzastaurin May Show Benefit in Subgroup of Patients with Diffuse Large B-Cell Lymphoma

August 25th 2020, 9:00pm

The agent, in combination with the current standard of care, is being evaluated as a frontline treatment for patients with high-risk Denovo Genomic Marker 1 (DGM1)–positive DLBCL.

FDA Approves Monjuvi-Revlimid Combo for Relapsed/Refractory DLBCL

August 1st 2020, 5:24am

The Food and Drug Administration approved Monjuvi in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

CURE's Top 5 Stories: July 2019

August 1st 2019, 8:00pm

Here are the top 5 CURE stories for July 2019.

What Being a Survivor Means to 'The Pink Hulk', a Three-Time Cancer Survivor

July 29th 2019, 10:48pm

Three-time cancer survivor and one-woman show writer and performer, Valerie David, sat down with CURE® to discuss life as a survivor.

Blending the Truth With Compassion in Cancer Care

July 27th 2019, 4:00pm

This essay describes my journey with non-Hodgkin lymphoma — peripheral T-cell, not otherwise specified — and my most extraordinary nurse, Xuan Arnette, RN, OCN.

Friday Frontline: Cancer Updates, Research and Education on July 26, 2019

July 26th 2019, 8:49pm

From landmark Senate legislation to the Pink Lemonade Stand Challenge, here’s what is making headlines in the cancer space this week.

FDA Approves Rituxan Biosimilar to Treat Blood Cancers

July 23rd 2019, 10:11pm

The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.

Future Management of Waldenstrom Macroglobulinemia

February 15th 2019, 9:08pm

BTK Inhibitors in WM: Understanding Safety/Efficacy

February 15th 2019, 9:08pm

Targeted Approaches in Waldenstrom Macroglobulinemia

February 15th 2019, 9:08pm